Oncology Service Line Director supporting Lymphedema Prevention

Complete Cancer Care includes a Lymphedema Prevention Program

Prevent Lymphedema with a 30-second, Noninvasive Test

Cancer-related lymphedema is one of the most serious sequelae associated with cancer treatment. Implementing a Lymphedema Prevention Program not only improves patients’ health, it can increase the value of your cancer center.  

Request a Demo

 

LPP-badge-spiral_sm-1

1 in 3 of at-risk cancer patients will develop lymphedema1,2

 

The Benefits of Establishing a Lymphedema Prevention Program

 

Attract & Retain More Patients

Provide specialized care and more effective treatment options by establishing a Lymphedema Prevention Plan (LPP). A comprehensive LPP allows cancer centers to attract more patients and retain them throughout adjuvant therapy.

 

Meet Accreditation Standards

Several cancer treatment guidelines recommend that patients be assessed for lymphedema using a pretreatment baseline test and regular post-surgical testing with a goal of early detection. Cancer centers offering a prevention program also meet quality metrics set by the NAPBC, APTA, eviCore® and COC.

 

Effectively Prevent Lymphedema

Utilize bioimpedance spectroscopy (BIS) technology to effectively monitor and measure a patient’s fluid status. A single SOZO® reading allows clinicians across multiple specialties to provide individualized, proactive care.

SOZO-test

Obtain Reliable, Precise Fluid Readings in Seconds

SOZO, the world’s most advanced, noninvasive bioimpedance spectroscopy (BIS) device, incorporates L-Dex® technology, The FDA-cleared, CE-marked and ARTG-listed digital health platform aids in the early detection of secondary lymphedema and can be used to monitor and maintain overall health.

Request a Demo

 

Guidelines for Implementing a Lymphedema Prevention Program

Test. Trigger. Treat.TM

Test

12

Test Upon Diagnosis & Periodically after Cancer Surgery

It is important to set a baseline L-Dex score once a patient is diagnosed with breast cancer, melanoma, or pelvic area cancers. After cancer surgery, it is recommended that patients get tested every 3 months for the first 3 years, every 6 months for years 4 and 5, and annually thereafter2.

 

Trigger

9

Evaluate Elevated L-Dex Readings above the Baseline

Clinical evidence shows that if a patient’s L-Dex score increases 6.5 or more from the baseline, that’s a “trigger” to evaluate the patient and initiate intervention3.

 

 

Treat

11

Apply Treatment to Reduce Lymphedema Progression

Treatment for patients diagnosed with early lymphedema, including standard compression garments worn at home for 4 weeks, 12 hours per day, has been shown to reduce the progression of lymphedema by 95% in breast cancer patients3.

Accurately Measure Fluid Status at Point of Care

Securely Share Data Across Your Healthcare System with MySOZO

The SOZO platform stores user accounts, patient records, measurement data, other calculated measures and trends in a proprietary and secure MySOZO cloud. This allows medical staff to quickly and easily share information with anyone with proper credentials.

 

SOZO Data Sharing1

Establish a Lymphedema Prevention Program for Your Cancer Center

Offering a lymphedema prevention plan will become essential to complete cancer care as the awareness of lymphedema prevention continues to grow among the medical and patient communities. Download our guide to learn more about the advantages of adding a lymphedema prevention program to your cancer care center.

Together, We Can End Cancer-Related Lymphedema

Contact us to learn about SOZO with L-Dex and the benefits of supporting a Lymphedema Prevention Program.

Request a Demo

  • References

    1. Shaitelman SF, et al. Recent Progress in the Treatment and Prevention of Cancer-Related Lymphedema. CA Cancer J Clin. 2015;00:00–00.

    2. Brown JC, et al. The Prevalence of Lymphedema Symptoms among Long-Term Cancer Survivors with or at-risk for Lower Limb Lymphedema. Am J Phys Med Rehabil. 2013 March ; 92(3): 223–231. doi:10.1097/PHM.0b013e31826edd97.

    3. Shah C, et al. Bioimpedance Spectroscopy for Breast Cancer Related Lymphedema Assessment: Clinical Practice Guidelines. The Breast Journal 2016;DOI: 10.1111/tbj.12647.

    4. Ridner SH, et al. A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement for the Prevention of Lymphedema Following Treatment for Breast Cancer: Interim Analysis. Ann Surg Oncol 2019; https://doi.org/10.1245/s10434-019-07344-5.